La Chaux-de-Fonds, Switzerland, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of DHODH in preclinical models of Acute Myeloid Leukemia (AML).
Highlights from the two posters include:
- RP7214 is a potent and novel DHODH inhibitor in AML acting via suppression of cellular pyrimidine pools and promoting differentiation to fully mature cells
- RP7214 demonstrated single-agent activity in AML cell lines and anti-tumor activities in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model
- RP7214 potentiated the activity of gilteritinib (XOSPATA) in reducing cell growth, induction of apoptosis, cell cycle arrest and inhibition of pAkt and pErk 1/2
- RP7214 demonstrated anti-tumor activities manifested by a reduction in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model when combined with cytarabine (ARA-C)
About RP7214:
RP7214 is a novel oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) with demonstrated preclinical activity in myeloid malignancies and solid tumors. The compound is currently being evaluated in IND-enabling tolerability studies with a Phase I clinical trial in Myeloid Malignancies expected to commence in 2020.
Details of the poster presentations:
-- Poster Title: Inhibition of Dihydroorotate Dehydrogenase (DHODH) by RP7214 attenuates growth and promotes differentiation of AML cell lines
- Session Title: Therapeutic Agents: Other
- Session Date: Tuesday, October 29, 2019
- Session Start Time: 12:30
- Session End Time: 16:00
- Location: Hall D, Hynes Convention Center
- Permanent Abstract No.: C042
-- Poster Title: RP7214, a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML
- Session Title: Therapeutic Agents: Other
- Session Date: Tuesday, October 29, 2019
- Session Start Time: 12:30
- Session End Time: 16:00
- Location: Hall D, Hynes Convention Center
- Permanent Abstract No.: C044
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.